Enliven Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

ELVN$51.55+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of	As of
	March 31, 2026	December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$132,184	$98,896
Marketable securities	320,217	363,725
Prepaid expenses and other current assets	10,736	12,257
Total current assets	463,137	474,878
Property and equipment, net	20	34
Operating lease right-of-use assets	290	383
Deferred offering costs	217	217
Other long-term assets	1,188	656
Total assets	$464,852	$476,168
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,640	$2,159
Accrued expenses and other current liabilities	9,847	14,409
Total current liabilities	11,487	16,568
Total liabilities	11,487	16,568
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none	—	—
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 60,889,655 and 59,440,045 atMarch 31, 2026 and December 31, 2025, respectively	61	59
Additional paid-in capital	824,479	806,373
Accumulated other comprehensive (loss) income	(382)	334
Accumulated deficit	(370,793)	(347,166)
Total stockholders’ equity	453,365	459,600
Total liabilities and stockholders' equity	$464,852	$476,168

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.